This study is for adults aged 18 and older who have obesity and a liver disease called non-alcoholic steatohepatitis (NASH) or metabolic associated steatohepatitis (MASH), with moderate or advanced liver damage (fibrosis). The study tests if a medicine named survodutide can help improve liver function. Participants are randomly placed into two groups: one gets survodutide and the other gets a placebo, which looks the same but has no medicine. Survodutide or placebo is injected under the skin weekly. Diet and exercise counseling is also provided.
The study lasts up to 7 years, with frequent visits at the start, gradually decreasing over time. Health checks, questionnaires, and liver imaging are done regularly. Sometimes, a small liver sample (biopsy) is taken. Participants and doctors do not know who is in which group.
- Study duration: Up to 7 years with regular visits
- Random assignment to medicine or placebo group
- Requires commitment to diet and exercise changes